DPT-IPV-Hib vaccine - Mitsubishi Tanabe Pharma Corporation

Drug Profile

DPT-IPV-Hib vaccine - Mitsubishi Tanabe Pharma Corporation

Alternative Names: BK 1310; MT 2355

Latest Information Update: 19 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Mitsubishi Tanabe Pharma Corporation; Research Foundation for Microbial Diseases of Osaka University
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 01 Jun 2017 Phase-III clinical trials in Diphtheria (In children, In infants, Prevention) in Japan (IM) (NCT03188692)
  • 01 Jun 2017 Phase-III clinical trials in Haemophilus infections (In children, In infants, Prevention) in Japan (IM) (NCT03188692)
  • 01 Jun 2017 Phase-III clinical trials in Pertussis (In children, In infants, Prevention) in Japan (IM) (NCT03188692)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top